Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial (Q28217976)

2

0 references

J van Gijn

3

0 references

L J Kappelle

4

0 references

P J Koudstaal

Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis.

5

0 references

language of work or name

English

0 references

publication date

February 2007

0 references

published in

Lancet Neurology

0 references

volume

6

0 references

issue

2

0 references

page(s)

115-24

0 references

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Secondary prevention of stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Design of ESPRIT: an international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

ESPRIT: protocol change.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

1 reference

7 January 2021

Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Interobserver agreement for the assessment of handicap in stroke patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Interobserver agreement for the assessment of handicap in stroke patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Grading white matter lesions on CT and MRI: a simple scale

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Severity of cerebral white matter lesions and infarcts in patients with transient or moderately disabling cerebral ischaemia: reproducibility of grading by neurologists

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Recurrent stroke after transient ischaemic attack or minor ischaemic stroke: does the distinction between small and large vessel disease remain true to type? Dutch TIA Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Type of stroke after transient monocular blindness or retinal infarction of presumed arterial origin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Classification of cause of death after stroke in clinical research

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

A Multiple Testing Procedure for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

Population based study of early risk of stroke after transient ischaemic attack or minor stroke: implications for public education and organisation of services

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970685-8

7 January 2021

10.1016/S1474-4422(06)70685-8

Identifiers

DOI

0 references

Fatcat ID

release_kuwcptbdlnhlxba6b5ix7hnpsy

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/kuwcptbdlnhlxba6b5ix7hnpsy

24 November 2022